Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Prevention of liver fibrosis and steatosis progression among heavy drinkers with and without HIV after 30-day drinking-reduction program

View ORCID ProfileSeungjun Ahn, Veronica Richards, Emmanuel Thomas, Dushyantha Jayaweera, Varan Govind, Zhigang Li, Ronald A. Cohen, Robert L. Cook
doi: https://doi.org/10.1101/2023.02.27.23286532
Seungjun Ahn
1Department of Biostatistics, University of Florida, Gainesville, FL 32611, U.S.A.
3Southern HIV and Alcohol Research Consortium, Emerging Pathogens Institute, Gainesville, FL 32610, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Seungjun Ahn
  • For correspondence: sahn1{at}ufl.edu
Veronica Richards
2Department of Epidemiology, University of Florida, Gainesville, FL 32611, U.S.A.
3Southern HIV and Alcohol Research Consortium, Emerging Pathogens Institute, Gainesville, FL 32610, U.S.A.
7Edna Bennett Pierce Prevention Research Center, Pennsylvania State University, University Park, PA 16802, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emmanuel Thomas
4Schiff Center for Liver Disease, University of Miami Miller School of Medicine, Miami, FL 33136, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dushyantha Jayaweera
4Schiff Center for Liver Disease, University of Miami Miller School of Medicine, Miami, FL 33136, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Varan Govind
6Department of Radiology, University of Miami Miller School of Medicine, Miami, FL 33136, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhigang Li
1Department of Biostatistics, University of Florida, Gainesville, FL 32611, U.S.A.
3Southern HIV and Alcohol Research Consortium, Emerging Pathogens Institute, Gainesville, FL 32610, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald A. Cohen
3Southern HIV and Alcohol Research Consortium, Emerging Pathogens Institute, Gainesville, FL 32610, U.S.A.
5Department of Clinical and Health Psychology, University of Florida, Gainesville, FL 32610, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert L. Cook
2Department of Epidemiology, University of Florida, Gainesville, FL 32611, U.S.A.
3Southern HIV and Alcohol Research Consortium, Emerging Pathogens Institute, Gainesville, FL 32610, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background This is the first attempt to assess changes in liver abnormalities before and after contingency management (CM) to reduce heavy drinking beyond 30-days of follow-up.

Objective The main objective was to determine whether liver fibrosis and steatosis, measured using FibroScan, change significantly between baseline, 30-days, and 90-days among older adults who drink heavily at baseline, enrolled in the CM intervention for alcohol reduction. The secondary aim of the study was to assess whether the changes in liver outcome measures differ across alcohol consumption categories.

Methods A prospective study (ClinicalTrials.gov registry: NCT03353701) of 46 older adults (63% male, 76.1% Black, mean age = 56.4) with heavy drinking at the baseline, living with or without HIV infection was evaluated. A linear mixed-effects model was used to analyze the FibroScan Transient Elastography (TE for fibrosis) and Controlled Attenuation Parameter (CAP for steatosis).

Results There were no significant changes in liver fibrosis and steatosis measures after 90-days of drinking abstinence among heavy drinkers with or without stratified TE or CAP values at baseline.

Conclusions CM for drinking reduction may not be effective at least short-term prospective in preventing liver fibrosis and steatosis progression for subjects without severe liver disease at baseline.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

ClinicalTrials.gov registry: NCT03353701

Clinical Protocols

https://clinicaltrials.gov/ct2/show/NCT03353701

Funding Statement

This research was supported by Award Number [NIH U01AA020797] and [NIH T32AA025877 to S.A.] from the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health and [NIH T32DA017629 to V.R.] from the National Institute on Drug Abuse of the National Institutes of Health.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Institutional Review Board at University of Miami (Study Number: 20170396).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

  • Abbreviations

    CM
    contingency management;
    TE
    Transient elastography;
    CAP
    Controlled attenuation parameter;
    HIV
    Human immunodeficiency virus;
    PLWH
    Persons living with HIV;
    NAFLD
    Non-alcoholic fatty liver disease;
    ALT
    aminotransferase;
    GGT
    gamma-glutamyl transferase;
    ALD
    Alcoholic-related liver disease;
    FIB-4
    Fibrosis-4;
    AST
    Aspartate aminotransferase;
    TLFB
    Alcohol timeline followback;
    HCV
    Hepatitis C
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
    Back to top
    PreviousNext
    Posted March 01, 2023.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Prevention of liver fibrosis and steatosis progression among heavy drinkers with and without HIV after 30-day drinking-reduction program
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Prevention of liver fibrosis and steatosis progression among heavy drinkers with and without HIV after 30-day drinking-reduction program
    Seungjun Ahn, Veronica Richards, Emmanuel Thomas, Dushyantha Jayaweera, Varan Govind, Zhigang Li, Ronald A. Cohen, Robert L. Cook
    medRxiv 2023.02.27.23286532; doi: https://doi.org/10.1101/2023.02.27.23286532
    Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    Prevention of liver fibrosis and steatosis progression among heavy drinkers with and without HIV after 30-day drinking-reduction program
    Seungjun Ahn, Veronica Richards, Emmanuel Thomas, Dushyantha Jayaweera, Varan Govind, Zhigang Li, Ronald A. Cohen, Robert L. Cook
    medRxiv 2023.02.27.23286532; doi: https://doi.org/10.1101/2023.02.27.23286532

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Gastroenterology
    Subject Areas
    All Articles
    • Addiction Medicine (349)
    • Allergy and Immunology (668)
    • Allergy and Immunology (668)
    • Anesthesia (181)
    • Cardiovascular Medicine (2648)
    • Dentistry and Oral Medicine (316)
    • Dermatology (223)
    • Emergency Medicine (399)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
    • Epidemiology (12228)
    • Forensic Medicine (10)
    • Gastroenterology (759)
    • Genetic and Genomic Medicine (4103)
    • Geriatric Medicine (387)
    • Health Economics (680)
    • Health Informatics (2657)
    • Health Policy (1005)
    • Health Systems and Quality Improvement (985)
    • Hematology (363)
    • HIV/AIDS (851)
    • Infectious Diseases (except HIV/AIDS) (13695)
    • Intensive Care and Critical Care Medicine (797)
    • Medical Education (399)
    • Medical Ethics (109)
    • Nephrology (436)
    • Neurology (3882)
    • Nursing (209)
    • Nutrition (577)
    • Obstetrics and Gynecology (739)
    • Occupational and Environmental Health (695)
    • Oncology (2030)
    • Ophthalmology (585)
    • Orthopedics (240)
    • Otolaryngology (306)
    • Pain Medicine (250)
    • Palliative Medicine (75)
    • Pathology (473)
    • Pediatrics (1115)
    • Pharmacology and Therapeutics (466)
    • Primary Care Research (452)
    • Psychiatry and Clinical Psychology (3432)
    • Public and Global Health (6527)
    • Radiology and Imaging (1403)
    • Rehabilitation Medicine and Physical Therapy (814)
    • Respiratory Medicine (871)
    • Rheumatology (409)
    • Sexual and Reproductive Health (410)
    • Sports Medicine (342)
    • Surgery (448)
    • Toxicology (53)
    • Transplantation (185)
    • Urology (165)